Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson L Michael

Showing results (321-330 of 372) with videos related to

Pageof 38
Sort By:
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Science Translational Medicine|September 20, 2019
Immune correlates of the Thai RV144 HIV vaccine regimen in South AfricaGlenda E Gray, Ying Huang, Nicole Grunenberg, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Iscience|October 1, 2024
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activityElizabeth J Martinez, William C Chang, Wei-Hung Chen, et al.
Virus Evolution|September 17, 2021
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infectionEric Lewitus, Eric Sanders-Buell, Meera Bose, et al.
Plos One|April 27, 2018
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvantYingxia Wen, Hung V Trinh, Christine E Linton, et al.
Nature Communications|June 9, 2017
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challengeTodd Bradley, Justin Pollara, Sampa Santra, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 38

Showing results (321-330 of 372) with videos related to

Sort By:
Pageof 38
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Science Translational Medicine|September 20, 2019
Immune correlates of the Thai RV144 HIV vaccine regimen in South AfricaGlenda E Gray, Ying Huang, Nicole Grunenberg, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Iscience|October 1, 2024
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activityElizabeth J Martinez, William C Chang, Wei-Hung Chen, et al.
Virus Evolution|September 17, 2021
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infectionEric Lewitus, Eric Sanders-Buell, Meera Bose, et al.
Plos One|April 27, 2018
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvantYingxia Wen, Hung V Trinh, Christine E Linton, et al.
Nature Communications|June 9, 2017
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challengeTodd Bradley, Justin Pollara, Sampa Santra, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 38